# AMR Bio Receives Supportive FDA Minutes for XF-73 Nasal Phase 3 Trial Design

> AMR Bio received FDA meeting minutes supporting its Phase 3 design for XF-73 Nasal, following a Phase 2b study showing a 99.5% reduction in S. aureus carriage.

- Published: 2026-11-16T09:28:57+00:00
- Section: Regulation & Approvals
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-16/amr-bio-fda-xf-73-phase-3
- Source: [Investegate](https://www.investegate.co.uk/announcement/rns/emv-capital--emvc/amr-bio-constructive-type-b-fda-meeting-for-xf-73/9875792)

## Key takeaways

- AMR Bio received official minutes from its Type B End-of-Phase 2 meeting with the FDA on the Phase 3 design for XF-73 Nasal.
- The FDA was supportive of the proposed Phase 3 trial design and gave recommendations that will inform the final design.
- AMR Bio expects to submit full Phase 3 protocols to the FDA in the coming months.
- XF-73 Nasal holds QIDP designation and Fast Track status from the FDA and an Innovation Passport in the UK.

AMR Bio has received official minutes from its Type B End-of-Phase 2 meeting with the U.S. Food and Drug Administration on the Phase 3 trial design for its lead product, XF-73 Nasal, the company's investor EMV Capital said in a [statement](https://www.investegate.co.uk/announcement/rns/emv-capital--emvc/amr-bio-constructive-type-b-fda-meeting-for-xf-73/9875792) published on November 16, 2026. The FDA was supportive of the proposed design and provided recommendations that will inform the final Phase 3 trial design.

## AMR Bio's XF-73 Nasal Phase 3 Plans

AMR Bio is a clinical-stage biotechnology company developing treatments to prevent infections without contributing to antimicrobial resistance. XF-73 is a first-in-class antimicrobial nasal gel intended for use in the 24 hours before surgery to reduce the nasal burden of Staphylococcus aureus, including MRSA, and prevent post-operative surgical site infections. Its mechanism of action disrupts the bacterial cell membrane and has shown a low propensity for resistance development.

The FDA meeting followed the completion of a Phase 2b clinical study in patients undergoing open-heart surgery, in which XF-73 achieved a 99.5% reduction in Staphylococcus aureus nasal carriage before surgery. AMR Bio will now incorporate the FDA's recommendations into its clinical development plans and expects to submit full Phase 3 protocols to the FDA in the coming months.

Nigel Brooksby, Executive Chair of AMR Bio, said: "This is an important milestone for XF-73 Nasal. We are very encouraged by the outcome of our EOP2 meeting and the FDA's supportive feedback on our proposed Phase 3 trial design." He added that the company's immediate priority is to incorporate the FDA's recommendations and move the Phase 3 programme forward, next progressing its CMC and CRO strategy.

XF-73 Nasal holds Qualified Infectious Disease Product designation and Fast Track status from the FDA, which provides an additional five years of US market exclusivity and eligibility for priority review and rolling submission. In the UK, it has been granted an Innovation Passport under the MHRA's Innovative Licensing and Access Pathway. AMR Bio was formed in September 2025 through EMV Capital's Venture Build programme, and [EMV Capital](https://akta.pro/company-profiles/0005zzn/emv-capital) holds a direct interest of 29.7%.

## Other Antibiotic Developers' Regulatory Moves

Wockhardt expanded access to its novel antibiotic Miqnaf and reported Q2 consolidated revenue of Rs 969 crore, up 24% year-on-year, [The Times of India](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/wockhardt-expands-novel-antibiotic-miqnafs-access-q2-revenue-rises-24/articleshow/135460959.cms) reported on November 2, 2026. The company also received US FDA approval for Zaynich for complicated urinary tract infections and plans to file for an additional Miqnaf indication in FY27.

Mirum Pharmaceuticals plans an FDA submission for its hepatitis D treatment after the drug succeeded in the second of two pivotal trials, [Endpoints News](https://endpoints.news/mirum-plans-fda-submission-for-hepatitis-d-treatment-as-competition-brews/) reported on November 10, 2026.

## AMR Bio's Next Regulatory Steps

AMR Bio expects to submit full Phase 3 protocols to the FDA in the coming months, according to the statement. The company said its immediate priority is to incorporate the FDA's recommendations and progress its CMC and CRO strategy.

## Companies in this story

- AMR Bio · website: https://amr-bio.com
- [EMV Capital company profile](https://akta.pro/company-profiles/0005zzn/emv-capital) · website: http://emvcapital.com

---
News for Agent · https://newsforagent.com/llms.txt
